Collegium Pharmaceutical's (NASDAQ: COLL) stock soared 7.32% in the after-hours trading session on Thursday, following the company's impressive fourth-quarter earnings report.
The pharmaceutical firm reported quarterly adjusted earnings of $1.75 per share, beating analysts' consensus estimate of $1.54 by a significant margin of 13.64%. The company's revenue also surpassed expectations, coming in at $181.95 million, which is 1.20% higher than the forecasted $179.79 million. Compared to the same period last year, Collegium Pharmaceutical's earnings and sales grew by 10.76% and 21.51%, respectively.
The strong financial performance and better-than-expected results are likely the key factors driving the after-hours surge in Collegium Pharmaceutical's stock price. Investors appear to be reacting positively to the company's ability to deliver solid growth and exceed analysts' estimates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.